EICHOR
● Not Yet Recruiting
Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases
Condition: Metastatic Colorectal Cancer · Sponsor: UNICANCER
About this study
The goal of this clinical trial is to evaluate the superiority of ivonescimab combined with FOLFIRI over FOLFIRI + bevacizumab as second-line treatment of non resectable pMMR/MSS BRAFwt mCRC patients without liver metastases in terms of PFS. The main questions it aims to answer are: Does FOLFIRI + ivonescimab improve progression-free survival compared to FOLFIRI + bevacizumab? Participants will: Take FOLFIRI + ivonescimab or FOLFIRI + bevacizumab every 2 weeks for a maximum of 24 months Visit the clinic once every 2 weeks for checkups and tests, and have imaging done every 8 weeks Complete some quality of life questionnaires every 8 weeks
This description comes directly from the study's public registry record.
Talk to the study team
Emilie Brument · 0668320359 · e-brument@unicancer.fr
Valérie BOIGE, MD · 0630582651 · Valerie.Boige@gustaveroussy.fr
Always discuss trial participation with your own doctor first.
Locations (22)
| CH d'Auxerre | Auxerre, France | — |
| Centre Hospitalier de Beuvry | Beuvry, France | — |
| Centre François Baclesse | Caen, France | — |
| CH de Calais | Calais, France | — |
| Polyclinique Saint Côme | Compiègne, France | — |
| Institut Andrée Dutreix | Coudekerque-Branche, France | — |
| Centre Oscar Lambret | Lille, France | — |
| Centre Léon Bérard | Lyon, France | — |
| Hôpital Européen de Marseille | Marseille, France | — |
| Hôpital la Timone | Marseille, France | — |
| Institut Paoli Calmettes | Marseille, France | — |
| CHRU de Nancy | Nancy, France | — |
+ 10 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07359456